The TPO receptor overexpressing vector was packaged into the lentivirus (Shanghai Biotechnology Co, Ltd., Shanghai, China). The 32D cells were infected with the constructed lentivirus according to the manufacturer’s protocol (Shanghai Biotechnology Co, Ltd.). For the serum treatment, the normal serum was obtained from healthy volunteers from Affiliated Hospital of Nantong University. The aplastic anemia serum was obtained from patients with aplastic anemia in the Affiliated Hospital of Nantong University between January 2016 and August 2017. The procedures were approved the Ethics Committee of Affiliated Hospital of Nantong University and each patient signed the informed consent. The 32D cells were treated with 10% serum from healthy subjects or 10% serum from aplastic anemia patients. For the TPO (Sigma) treatment, different concentrations of TPO (50, 100, 150, and 200 U/ml) were used to treat 32D cells for 24 h before further experimental assays.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.